真性红细胞增多症的突变图谱:表型、基因型与预后相关性
研究对319例真性红细胞增多症(PV)患者进行二代测序,其中270例(85%)在诊断或慢性期(A组),37例(12%)在纤维化转化时(B组),12例(4%)在白血病转化时(C组)。TP53/SRSF2/IDH1/U2AF1突变频率在A、B、C三组间有显著差异(p<0.05)。在A组中,SRSF2、IDH2、ASXL1突变及白细胞≥15×10^9/L、高龄为总生存期不良因素。
要点
- PV患者中超过50%携带非JAK2突变,TP53/SRSF2/IDH1/U2AF1频率在慢性期、纤维化转化和白血病转化三组间差异显著。
- A组中SRSF2、IDH2、ASXL1突变及白细胞≥15×10^9/L、高龄是多变量分析中总生存期的独立不良因素。
- 存在任何不良突变(SRSF2/ASXL1/IDH2)者中位总生存期8.8年 vs 无不良突变者17.8年(p=0.01;HR 1.8,1.1-2.9)。
核心结论
- 非JAK2突变在PV中具有预后意义,并可能被纳入未来的预后模型。
研究设计与样本
- 研究纳入319例PV患者,在诊断或慢性期(A组,N=270,85%)、纤维化转化时(B组,N=37,12%)或白血病转化时(C组,N=12,4%)进行二代测序。
- 表型/基因型关联及对总生存期(OS)、无白血病生存期(LFS)和无骨髓纤维化生存期(MFFS)的预后分析仅限于A组患者。
主要发现
- TP53/SRSF2/IDH1/U2AF1突变频率在A组(2%/4%/2%/0.4%)、B组(8%/0%/0%/5%)和C组(50%/25%/17%/8%)间差异显著(p<0.05)。
- A组中ASXL1突变与较年轻年龄相关(p<0.01),SRSF2突变与较老年龄和白细胞增多相关(p<0.01),TP53突变与白细胞增多相关(p<0.01)。
- 突变共 segregated:ASXL1与IDH2(p<0.01)或SRSF2(p<0.01)、SRSF2与IDH2(p<0.01)、TP53与NRAS(p=0.01)。
- 多变量分析显示SRSF2突变(p<0.01;HR 4.2,1.9-9.5)、IDH2突变(p=0.01;HR 5.3,1.8-15.3)、ASXL1突变(p=0.04;HR 2.0,1.1-3.7)、白细胞计数≥15×10^9/L(p<0.01;HR 2.0,1.3-3.1)和高龄(p<0.01)为OS的危险因素。
- 存在任何不良突变(SRSF2、ASXL1或IDH2)者(N=235;87%)与无不良突变者(N=35;13%)的中位OS分别为8.8年和17.8年(p=0.01;HR 1.8,1.1-2.9)。
关键数值与推荐
- LFS相关:ASXL1突变(p=0.02;HR 1.6-24.9)、SRSF2突变(p=0.06;HR 11.9,1.1-126.2)和高龄(p=0.04)与较差LFS相关。
- MFFS相关:SRSF2突变(p<0.01;HR 24.0,5.5-103.8)和异常核型(p<0.01;HR 3.8,1.6-8.9)与较差MFFS相关。
- 非JAK2突变数量在单变量分析中可预测结局,但在多变量分析中不显著。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Polycythemia vera (PV) is invariably associated with a JAK2 mutation, with over 50% of patients harboring additional non-JAK2 mutations. In the current study, 319 patients with PV underwent NGS at diagnosis or in chronic phase PV (Group A: N = 270, 85%) or at the time of fibrotic (Group B; N = 37, 12%) or leukemic (Group C; N = 12, 4%) transformation. Mutational frequencies involving TP53/SRSF2/IDH1/U2AF1 were significantly (p < 0.05) different between patients in the mutually exclusive Groups A (2%/4%/2%/0.4%), B (8%/0%/0%/5%), and C (50%/25%/17%/8%). Analyses on phenotype/genotype associations and prognostic impact on overall (OS), leukemia-free (LFS), and myelofibrosis-free (MFFS) survival were limited to Group A patients. ASXL1MUT was associated with younger age (p < 0.01), SRSF2MUT with older age and leukocytosis (p < 0.01), and TP53MUT with leukocytosis (p < 0.01). Mutation co-segregation was apparent between ASXL1 and IDH2 (p < 0.01) or SRSF2 (p < 0.01), SRSF2 and IDH2 (p < 0.01), and TP53 and NRAS (p = 0.01). Multivariable analysis identified SRSF2MUT (p < 0.01; HR, 4.2, 1.9-9.5), IDH2MUT (p = 0.01; HR, 5.3, 1.8-15.3), ASXL1MUT (p = 0.04; HR, 2.0, 1.1-3.7), leukocyte count ≥ 15 × 109/L (p < 0.01; HR 2.0, 1.3-3.1), and advanced age (p < 0.01) as risk factors for OS. Median OS in the presence (N = 235; 87%) or absence (N = 35; 13%) of any adverse mutation (i.e., SRSF2MUT, ASXL1MUT, or IDH2MUT) was 8.8 versus 17.8 years (p = 0.01; HR 1.8, 1.1-2.9). In addition, ASXL1MUT (p = 0.02; HR, 1.6-24.9), SRSF2MUT (p = 0.06; HR, 11.9, 1.1-126.2), and advanced age (p = 0.04) were associated with inferior LFS, and SRSF2MUT (p < 0.01; HR, 24.0, 5.5-103.8) and abnormal karyotype (p < 0.01; HR 3.8, 1.6-8.9) with inferior MFFS. The number of non-JAK2 mutations was significant in predicting outcome in univariate but not multivariable analysis. The observations from the current study highlight the prognostic significance of non-JAK2 mutations in PV and the prospect of their inclusion in future prognostic models.
引用
- Rana MS, Iftikhar M, Jadoon Y, et al. The Mutational Landscape in Polycythemia Vera: Phenotype, Genotype, and Prognostic Correlates. Am J Hematol. 2025. PMID: 40372079. doi:10.1002/ajh.27717
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。